Alejandro E. Mayorca-Guiliani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandro E. Mayorca-Guiliani has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Janine Terra Erler
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Denmark
7 shared publications - Chris Denis Madsen
Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden
4 shared publications - Maria Rafaeva
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark
3 shared publications Oliver Willacy
Biotech Research and Innovation Center, Faculty of Health Sciences, University of Copenhagen. Denmark.; Department of Pathology, Rigshospitalet, University Hospital of Copenhagen. Denmark
3 shared publications- Raphael Reuten
Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
3 shared publications Chris D. Madsen
Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University. Lund, Sweden
2 shared publications
Latest Publications
- Open Access
- 8 April 2025
- Published by Wiley in Liver International Communications
- Vol. 6 (2)
ECM Biomarkers PRO‐C3 and PRO‐C6 Reveal the Anti‐Fibrotic Effect of the Insulin Sensitizer MSDC‐0602 K During EMMINENCE Randomised Clinical Trial
MSDC‐0602 K is a second‐generation insulin sensitizer that inhibits the mitochondrial pyruvate carrier without activating the transcription factor PPARγ. The EMMINENCE phase IIb trial evaluated MSDC‐0602 K in patients with metabolic dysfunction‐associated steatohepatitis (MASH). MSDC‐0602 K missed statistical significance on endpoints based on liver histology while producing significant reductions in metabolic biomarkers. Here, we assessed the extracellular matrix‐based biomarkers PRO‐C3 and PRO‐C6, surrogates of collagen type III synthesis and the profibrotic, pro‐inflammatory fragment endotrophin. 392 MASH patients were randomised to placebo (PL), 62.5 mg, 125 mg or a 250 mg daily dose of MSDC‐0602 K for 12 months. 334 completed the study. The primary efficacy endpoint was defined as an improvement of ≥ 2 points in NAS score, with ≥ 1 decrease in either ballooning or inflammation and no increase in fibrosis stage. Blood samples were collected at baseline, 6 months, and 12 months to assess biochemical markers PRO‐C3 and PRO‐C6. The 125 mg and 250 mg doses of MSDC‐0602 K reduced PRO‐C3 at 6 months (p = 0.0103 and p = 0.026 respectively) and 12 months (p = 0.0274 and p = 0.0311) compared to placebo. Furthermore, the 62.5 mg and 250 mg doses reduced PRO‐C6 at 12mo (p = 0.0467 and p = 0.0266) compared to placebo. Treated patients who reached the primary endpoint had lower baseline PRO‐C3 (p = 0.026), and PRO‐C3 levels discriminated between regressing, stable or progressing fibrosis (p = 0.0076). MSDC‐0602 K significantly reduced PRO‐C3 and PRO‐C6, suggesting anti‐fibrotic and pro‐metabolic effects. Lower baseline fibroblast activity (PRO‐C3) at baseline was associated with improvement in fibrosis, while higher baseline PRO‐C3 was associated with fibrosis progression. Our findings suggest that MSDC‐0602 K has anti‐fibrogenesis and pro‐metabolic effects not detected by liver histology.Trial Registration: EMMINENCE clinical trial number (ClinicalTrials.gov NCT02784444)
- 8 April 2025
- Published by Wiley in Liver International Communications
- Vol. 6 (2)
Open AccessECM Biomarkers PRO‐C3 and PRO‐C6 Reveal the Anti‐Fibrotic Effect of the Insulin Sensitizer MSDC‐0602 K During EMMINENCE Randomised Clinical Trial
MSDC‐0602 K is a second‐generation insulin sensitizer that inhibits the mitochondrial pyruvate carrier without activating the transcription factor PPARγ. The EMMINENCE phase IIb trial evaluated MSDC‐0602 K in patients with metabolic dysfunction‐associated steatohepatitis (MASH). MSDC‐0602 K missed statistical significance on endpoints based on liver histology while producing significant reductions in metabolic biomarkers. Here, we assessed the extracellular matrix‐based biomarkers PRO‐C3 and PRO‐C6, surrogates of collagen type III synthesis and the profibrotic, pro‐inflammatory fragment endotrophin. 392 MASH patients were randomised to placebo (PL), 62.5 mg, 125 mg or a 250 mg daily dose of MSDC‐0602 K for 12 months. 334 completed the study. The primary efficacy endpoint was defined as an improvement of ≥ 2 points in NAS score, with ≥ 1 decrease in either ballooning or inflammation and no increase in fibrosis stage. Blood samples were collected at baseline, 6 months, and 12 months to assess biochemical markers PRO‐C3 and PRO‐C6. The 125 mg and 250 mg doses of MSDC‐0602 K reduced PRO‐C3 at 6 months (p = 0.0103 and p = 0.026 respectively) and 12 months (p = 0.0274 and p = 0.0311) compared to placebo. Furthermore, the 62.5 mg and 250 mg doses reduced PRO‐C6 at 12mo (p = 0.0467 and p = 0.0266) compared to placebo. Treated patients who reached the primary endpoint had lower baseline PRO‐C3 (p = 0.026), and PRO‐C3 levels discriminated between regressing, stable or progressing fibrosis (p = 0.0076). MSDC‐0602 K significantly reduced PRO‐C3 and PRO‐C6, suggesting anti‐fibrotic and pro‐metabolic effects. Lower baseline fibroblast activity (PRO‐C3) at baseline was associated with improvement in fibrosis, while higher baseline PRO‐C3 was associated with fibrosis progression. Our findings suggest that MSDC‐0602 K has anti‐fibrogenesis and pro‐metabolic effects not detected by liver histology.Trial Registration: EMMINENCE clinical trial number (ClinicalTrials.gov NCT02784444)
- 31 December 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 195, 94-103
Machine learning identifies remodeling patterns in human lung extracellular matrix
- 31 December 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 195, 94-103
Machine learning identifies remodeling patterns in human lung extracellular matrix
- 12 April 2022
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 22 (6) , 320-321
In situ decellularization of tissues to resolve the tumour-associated matrix
- 12 April 2022
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 22 (6) , 320-321
In situ decellularization of tissues to resolve the tumour-associated matrix
- Open Access
- 3 November 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (1) , 2100684
Modeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor
Metastatic cancer spread is responsible for most cancer-related deaths. To colonize a new organ, invading cells adapt to, and remodel, the local extracellular matrix (ECM), a network of proteins and proteoglycans underpinning all tissues, and a critical regulator of homeostasis and disease. However, there is a major lack in tools to study cancer cell behavior within native three-dimensional ECM. Here, we present an in-house designed bioreactor, where mouse organ ECM scaffolds are perfused and populated with cells that are challenged to colonize it. Using a specialized bioreactor chamber, it is possible to monitor cell behavior microscopically (e.g., proliferation, migration) within the organ scaffold. Cancer cells in this system recapitulate cell signaling observed in vivo and remodel complex native ECM. Moreover, our bioreactors are compatible with co-culturing cell types of different genetic origin comprising the normal and tumor microenvironment. This degree of experimental flexibility in an organ-specific and three-dimensional context, opens new possibilities to study cell-cell and cell-ECM interplay, and to model diseases in a controllable organ-specific system ex vivo. This article is protected by copyright. All rights reserved
- 3 November 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (1) , 2100684
Open AccessModeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor
Metastatic cancer spread is responsible for most cancer-related deaths. To colonize a new organ, invading cells adapt to, and remodel, the local extracellular matrix (ECM), a network of proteins and proteoglycans underpinning all tissues, and a critical regulator of homeostasis and disease. However, there is a major lack in tools to study cancer cell behavior within native three-dimensional ECM. Here, we present an in-house designed bioreactor, where mouse organ ECM scaffolds are perfused and populated with cells that are challenged to colonize it. Using a specialized bioreactor chamber, it is possible to monitor cell behavior microscopically (e.g., proliferation, migration) within the organ scaffold. Cancer cells in this system recapitulate cell signaling observed in vivo and remodel complex native ECM. Moreover, our bioreactors are compatible with co-culturing cell types of different genetic origin comprising the normal and tumor microenvironment. This degree of experimental flexibility in an organ-specific and three-dimensional context, opens new possibilities to study cell-cell and cell-ECM interplay, and to model diseases in a controllable organ-specific system ex vivo. This article is protected by copyright. All rights reserved
- 30 May 2021
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 171,p. e61854
Decellularization of the Murine Cardiopulmonary Complex
We present here a decellularization protocol for mouse heart and lungs. It produces structural ECM scaffolds that can be used to analyze ECM topology and composition. It is based on a microsurgical procedure designed to catheterize the trachea and aorta of a euthanized mouse to perfuse the heart and lungs with decellularizing agents. The decellularized cardiopulmonary complex can subsequently be immunostained to reveal the location of structural ECM proteins. The whole procedure can be completed in 4 days. The ECM scaffolds resulting from this protocol are free of dimensional distortions. The absence of cells enables structural examination of ECM structures down to submicron resolution in 3D. This protocol can be applied to healthy and diseased tissue from mice as young as 4-weeks old, including mouse models of fibrosis and cancer, opening the way to determine ECM remodeling associated with cardiopulmonary disease.
- 30 May 2021
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 171,p. e61854
Decellularization of the Murine Cardiopulmonary Complex
We present here a decellularization protocol for mouse heart and lungs. It produces structural ECM scaffolds that can be used to analyze ECM topology and composition. It is based on a microsurgical procedure designed to catheterize the trachea and aorta of a euthanized mouse to perfuse the heart and lungs with decellularizing agents. The decellularized cardiopulmonary complex can subsequently be immunostained to reveal the location of structural ECM proteins. The whole procedure can be completed in 4 days. The ECM scaffolds resulting from this protocol are free of dimensional distortions. The absence of cells enables structural examination of ECM structures down to submicron resolution in 3D. This protocol can be applied to healthy and diseased tissue from mice as young as 4-weeks old, including mouse models of fibrosis and cancer, opening the way to determine ECM remodeling associated with cardiopulmonary disease.
- Open Access
- 16 March 2020
- Published by Springer Nature in Nature Protocols
- Vol. 15 (6) , 2140
Author Correction: Decellularization and antibody staining of mouse tissues to map native extracellular matrix structures in 3D
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 16 March 2020
- Published by Springer Nature in Nature Protocols
- Vol. 15 (6) , 2140
Open AccessAuthor Correction: Decellularization and antibody staining of mouse tissues to map native extracellular matrix structures in 3D
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 8 November 2019
- Published by Springer Nature in Nature Protocols
- Vol. 14 (12) , 3395-3425
Decellularization and antibody staining of mouse tissues to map native extracellular matrix structures in 3D
The extracellular matrix (ECM) is a major regulator of homeostasis and disease, yet the 3D structure of the ECM remains poorly understood because of limitations in ECM visualization. We recently developed an ECM-specialized method termed in situ decellularization of tissues (ISDoT) to isolate native 3D ECM scaffolds from whole organs in which ECM structure and composition are preserved. Here, we present detailed surgical instructions to facilitate decellularization of 33 different mouse tissues and details of validated antibodies that enable the visualization of 35 mouse ECM proteins. Through mapping of these ECM proteins, the structure of the ECM can be determined and tissue structures visualized in detail. In this study, perfusion decellularization is presented for bones, skeletal muscle, tongue, salivary glands, stomach, duodenum, jejunum/ileum, large intestines, mesentery, liver, gallbladder, pancreas, trachea, bronchi, lungs, kidneys, urinary bladder, ovaries, uterine horn, cervix, adrenal gland, heart, arteries, veins, capillaries, lymph nodes, spleen, peripheral nerves, eye, outer ear, mammary glands, skin, and subcutaneous tissue. Decellularization, immunostaining, and imaging take 4–5 d.
- 8 November 2019
- Published by Springer Nature in Nature Protocols
- Vol. 14 (12) , 3395-3425
Decellularization and antibody staining of mouse tissues to map native extracellular matrix structures in 3D
The extracellular matrix (ECM) is a major regulator of homeostasis and disease, yet the 3D structure of the ECM remains poorly understood because of limitations in ECM visualization. We recently developed an ECM-specialized method termed in situ decellularization of tissues (ISDoT) to isolate native 3D ECM scaffolds from whole organs in which ECM structure and composition are preserved. Here, we present detailed surgical instructions to facilitate decellularization of 33 different mouse tissues and details of validated antibodies that enable the visualization of 35 mouse ECM proteins. Through mapping of these ECM proteins, the structure of the ECM can be determined and tissue structures visualized in detail. In this study, perfusion decellularization is presented for bones, skeletal muscle, tongue, salivary glands, stomach, duodenum, jejunum/ileum, large intestines, mesentery, liver, gallbladder, pancreas, trachea, bronchi, lungs, kidneys, urinary bladder, ovaries, uterine horn, cervix, adrenal gland, heart, arteries, veins, capillaries, lymph nodes, spleen, peripheral nerves, eye, outer ear, mammary glands, skin, and subcutaneous tissue. Decellularization, immunostaining, and imaging take 4–5 d.
- 12 June 2017
- Published by Springer Nature in Nature Medicine
- Vol. 23 (7) , 890-898
ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix
The extracellular matrix (ECM) is a master regulator of cellular phenotype and behavior. It has a crucial role in both normal tissue homeostasis and disease pathology. Here we present a fast and efficient approach to enhance the study of ECM composition and structure. Termed in situ decellularization of tissues (ISDoT), it allows whole organs to be decellularized, leaving native ECM architecture intact. These three-dimensional decellularized tissues can be studied using high-resolution fluorescence and second harmonic imaging, and can be used for quantitative proteomic interrogation of the ECM. Our method is superior to other methods tested in its ability to preserve the structural integrity of the ECM, facilitate high-resolution imaging and quantitatively detect ECM proteins. In particular, we performed high-resolution sub-micron imaging of matrix topography in normal tissue and over the course of primary tumor development and progression to metastasis in mice, providing the first detailed imaging of the metastatic niche. These data show that cancer-driven ECM remodeling is organ specific, and that it is accompanied by comprehensive changes in ECM composition and topological structure. We also describe differing patterns of basement-membrane organization surrounding different types of blood vessels in healthy and diseased tissues. The ISDoT procedure allows for the study of native ECM structure under normal and pathological conditions in unprecedented detail.
- 12 June 2017
- Published by Springer Nature in Nature Medicine
- Vol. 23 (7) , 890-898
ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix
The extracellular matrix (ECM) is a master regulator of cellular phenotype and behavior. It has a crucial role in both normal tissue homeostasis and disease pathology. Here we present a fast and efficient approach to enhance the study of ECM composition and structure. Termed in situ decellularization of tissues (ISDoT), it allows whole organs to be decellularized, leaving native ECM architecture intact. These three-dimensional decellularized tissues can be studied using high-resolution fluorescence and second harmonic imaging, and can be used for quantitative proteomic interrogation of the ECM. Our method is superior to other methods tested in its ability to preserve the structural integrity of the ECM, facilitate high-resolution imaging and quantitatively detect ECM proteins. In particular, we performed high-resolution sub-micron imaging of matrix topography in normal tissue and over the course of primary tumor development and progression to metastasis in mice, providing the first detailed imaging of the metastatic niche. These data show that cancer-driven ECM remodeling is organ specific, and that it is accompanied by comprehensive changes in ECM composition and topological structure. We also describe differing patterns of basement-membrane organization surrounding different types of blood vessels in healthy and diseased tissues. The ISDoT procedure allows for the study of native ECM structure under normal and pathological conditions in unprecedented detail.
- Open Access
- 1 November 2013
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 1729-35
The potential for targeting extracellular LOX proteins in human malignancy
Peer reviewed article authored by (Mayorca-Guiliani A, Erler JT). Read article or submit your manuscript for publishing.
- 1 November 2013
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 1729-35
Open AccessThe potential for targeting extracellular LOX proteins in human malignancy
Peer reviewed article authored by (Mayorca-Guiliani A, Erler JT). Read article or submit your manuscript for publishing.
- 1 August 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (8) , 663-670
Premetastatic vasculogenesis in oral squamous cell carcinoma xenograft-draining lymph nodes
- 1 August 2012
- Published by Elsevier in Oral Oncology
- Vol. 48 (8) , 663-670
Premetastatic vasculogenesis in oral squamous cell carcinoma xenograft-draining lymph nodes